Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection

American Journal of Pathology

Volumn 181, Issue 1, 2012, Pages 151-162

  Wilkison, Michelle ^a   Gauss, Katherine ^a   Ran, Yanchao ^a   Searles, Steve ^a   Taylor, David ^a   Meissner, Nicole ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; INTERFERON; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE FRAGILITY; BONE MARROW DEPRESSION; BONE MASS; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; CELL DIFFERENTIATION; CYTOKINES; DIPHOSPHONATES; DISEASE PROGRESSION; FEMUR; HEMOGLOBINURIA, PAROXYSMAL; INTERFERON TYPE I; MICE; MICE, KNOCKOUT; MICE, SCID; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; PNEUMONIA, PNEUMOCYSTIS; RANK LIGAND; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-RAY MICROTOMOGRAPHY;

EID: 84862690777     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.03.023     Document Type: Article

References (71)

1. Siegal F: Interferon-producing plasmacytoid dendritic cells and the pathogenesis of AIDS. Res Initiat Treat Action 2003, 8:10-13
2. Levy JA: The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001, 22:312-316
3. Sepkowitz KA: Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002, 34:1098-1107
4. Zandman-Goddard G, Shoenfeld Y: HIV and autoimmunity. Autoimmun Rev 2002, 1:329-337
5. Isgro A, Mezzaroma I, Aiuti A, De Vita L, Franchi F, Pandolfi F, Alario C, Ficara F, Riva E, Antonelli G, Aiuti F: Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000, 16:1471-1479
6. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998, 91:1479-1495
7. Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chene G, Mussini C, Porter K, Bucher HC. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy - the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med 2010, 7:e1000239
8. Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC: CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007, 12:889-897
9. Levy DE, Marie I, Prakash A: Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol 2003, 15:52-58
10. van Boxel-Dezaire AH, Rani MR, Stark GR: Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372
11. Levy JA, Scott I, Mackewicz C: Protection from HIV/AIDS: the importance of innate immunity. Clin Immunol 2003, 108:167-174
12. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, Huang L, Levy JA, Liu YJ: Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001, 98:906-912
13. Hosmalin A, Lebon P: Type I interferon production in HIV-infected patients. J Leukoc Biol 2006, 80:984-993
14. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, Adelsberger J, Baseler M, Maldarelli F, Davey R, Roby G, Rehm C, Lane C. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis HIV, type I IFN, and IL-7. J Immunol 2011, 186:2106-2116
15. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM: HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 2008, 3:e2961
16. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801
17. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011, 117:5582-5590
18. Siegal FP, Fitzgerald-Bocarsly P, Holland BK, Shodell M: Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 2001, 15:1603-1612
19. Hull MW, Phillips P, and Montaner JS: Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008, 134:1287-1298
20. Grubb JR, Moorman AC, Baker RK, Masur H: The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006, 20:1095-1107
21. Chew NS, Doran PP, and Powderly WG: Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Curr Opin HIV AIDS 2007, 2:318-323
22. Barkhordarian A, Ajaj R, Ramchandani MH, Demerjian G, Cayabyab R, Danaie S, Ghodousi N, Iyer N, Mahanian N, Phi L, Giroux A, Manfrini E, Neagos N, Siddiqui M, Cajulis OS, Brant XM, Shapshak P, Chiappelli F. Osteoimmunopathology in HIV/AIDS: a translational evidence-based perspective. Patholog Res Int 2011, 2011:359242
23. Bongiovanni M, Tincati C: Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical management. Curr Mol Med 2006, 6:395-400
24. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y: Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63
25. Takayanagi H: Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009, 5:667-676
26. Wilson A, Trumpp A: Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006, 6:93-106
27. Adams GB, Scadden DT: The hematopoietic stem cell in its place. Nat Immunol 2006, 7:333-337
28. Yin T, Li L: The stem cell niches in bone. J Clin Invest 2006, 116:1195-1201
29. Mundy GR: Osteoporosis and inflammation. Nutr Rev 2007, 65:S147-S151
30. Kamen DL, Alele JD. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010, 17:540-545
31. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis 2011, 5:217-224
32. Palange P, Testa U, Huertas A, Calabro L, Antonucci R, Petrucci E, Pelosi E, Pasquini L, Satta A, Morici G, Vignola MA, Bonsignore MR: Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006, 27:529-541
33. Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174
34. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R, Chiodo F, Re MC: RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007, 79:1446-1454
35. Yong MK, Elliott JH, Woolley IJ, Hoy JF: Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr 2011, 57:205-10
36. Kaur N, Mahl TC: Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484
37. Kaur N, Mahl TC: Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig Dis Sci 2004, 49:1458-1460
38. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, Tanaka Y, Takeuchi T, Miyasaka N: Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009, 61:305-312
39. Morris A, Alexander T, Radhi S, Lucht L, Sciurba FC, Kolls JK, Srivastava R, Steele C, Norris KA: Airway obstruction is increased in pneumocystis- colonized human immunodeficiency virus-infected outpatients. J Clin Microbiol 2009, 47:3773-3776
40. Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, Rogatsky I. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 30:4564-4574
41. Bhattacharyya S, Zhao Y, Kay TW, Muglia LJ. Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci U S A 2011, 108:9554-9559
42. Meissner N, Rutkowski M, Harmsen AL, Han S, Harmsen AG: Type I interferon signaling and B cells maintain hemopoiesis during Pneumocystis infection of the lung. J Immunol 2007, 178:6604-6615
43. Taylor D, Wilkison M, Voyich J, Meissner N. Prevention of bone marrow cell apoptosis and regulation of hematopoiesis by type I IFNs during systemic responses to pneumocystis lung infection. J Immunol 2011, 186:5956-5967
44. Kanzaki S, Takada Y, Ogawa K, Matsuo K: Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin. J Bone Miner Res 2009, 24:43-49
45. Harmsen AG, Stankiewicz M: Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990, 172:937-945
46. Bolliger AP: Cytologic evaluation of bone marrow in rats: indications, methods, and normal morphology. Vet Clin Pathol 2004, 33:58-67
47. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL: 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002, 277:14221-14226
48. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319
49. Parfitt AM: Bone histomorphometry: proposed system for standardization of nomenclature, symbols, and units. Calcif Tissue Int 1988, 42:284-286
50. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610
51. Bagi CM, Hanson N, Andresen C, Pero R, Lariviere R, Turner CH, Laib A: The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA. Bone 2006, 38:136-144
52. Taichman RS: Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005, 105:2631-2639
53. Kollet O, Dar A, Lapidot T: The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 2007, 25:51-69
54. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474
55. Secchiero P, Zauli G: Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008, 15:42-48
56. Wu Y, Humphrey MB, Nakamura MC: Osteoclasts: the innate immune cells of the bone. Autoimmunity 2008, 41:183-194
57. Harada S, Rodan GA: Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355
58. Takayanagi H, Kim S, Taniguchi T: Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002, 4 Suppl 3:S227-S232
59. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, Huang L, Norris KA: Association of chronic obstructive pulmonary disease severity and pneumocystis colonization. Am J Respir Crit Care Med 2004, 170:408-413
60. Morris A, Sciurba FC, Norris KA: Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease? COPD 2008, 5:43-51
61. Isgro A, Aiuti A, Leti W, Gramiccioni C, Esposito A, Mezzaroma I, and Aiuti F: Immunodysregulation of HIV disease at bone marrow level. Autoimmun Rev 2005, 4:486-490
62. Isgro A, Aiuti A, Mezzaroma I, Ruco L, Pinti M, Cossarizza A, Aiuti F: HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2005, 21:51-57
63. Suda T, Tanaka S, Takahashi N: Macrophage colon-stimulating factor (M-CSF) is essential for differentiation rather than proliferation of osteoclast progenitors. Osteoporos Int 1993, 3 Suppl 1:111-113
64. Tanaka S, Nakamura K, Takahasi N, Suda T: Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005, 208:30-49
65. Chang EY, Guo B, Doyle SE, Cheng G: Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol 2007, 178:6705-6709
66. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB: Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006, 203:1891-1901
67. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223
68. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749
69. Lum JJ, Bren G, McClure R, Badley AD: Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand. J Immunol 2005, 175:1232-1238
70. Kakagianni T, Giannakoulas NC, Thanopoulou E, Galani A, Michalopoulou S, Kouraklis-Symeonidis A, Zoumbos NC: A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res 2006, 30:713-721
71. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846